Plaque reduction neutralization test

Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Branches of biology, Medicine, Antibodies, Neutralizing antibody, Immunologic tests, Virology, Reporter virus particles, Plaque reduction neutralization test

Neutralizing antibodies have been scientifically shown to play a major role in preventing infection by blocking a virus from infecting cells.

Key Points: 
  • Neutralizing antibodies have been scientifically shown to play a major role in preventing infection by blocking a virus from infecting cells.
  • Developed by Professor Linfa Wang and his team from Duke-NUS,the sVNT neutralization antibody detectiontechnology is exclusively licensed to GenScript for commercializationas the cPass SARS-CoV-2 Neutralization Antibody Test.
  • "GenScript is honored to have been involved in the R&D and commercialization of the cPass kit.
  • The cPass test is a safer, faster, easier and more consistent alternative to the traditional live virus- or cell-based tests, with comparable specificity and sensitivity.

Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

Retrieved on: 
Wednesday, May 26, 2021
Medical specialties, Medicine, Clinical medicine, Immunologic tests, Antibodies, Neutralizing antibody, COVID-19, Titer, Plaque reduction neutralization test

The serum neutralizing antibody titers were determined using a live virus focus reduction neutralization titer (FRNT) assay with a 50% neutralization endpoint.

Key Points: 
  • The serum neutralizing antibody titers were determined using a live virus focus reduction neutralization titer (FRNT) assay with a 50% neutralization endpoint.
  • Importantly, AdCOVID also promoted a strong mucosal neutralizing response to the B.1.351 virus in the respiratory tract with bronchoalveolar lavages showing neutralization of the variant virus.
  • AdCOVID is a single-dose intranasal vaccine candidate for COVID-19 currently being evaluated in a Phase 1 clinical trial.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Retrieved on: 
Wednesday, July 22, 2020
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Virology, Medical specialties, Laboratory techniques, Zoonoses, Natural sciences, Chemistry, Plaque reduction neutralization test, Peplomer, Coronavirus disease, NIHS, CoV, Assay

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.
  • The NIHs preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay.
  • In March 2020 Noachis Terra Inc., a wholly owned subsidiary of Oragenics, acquired a non-exclusive license from the NIH for this stabilized prefusion CoV-2 spike protein.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.